Patent US2615878A successfully refreshed from Google Patents.
Patent US5304595A successfully refreshed from Google Patents.
US5304595A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Collagen-polymer conjugates
Assignee: Angiodevice International GmbH
•
Filing: 1992-12-30
•
Granted: 1994-04-19
•
Expires: 2012-12-30
Abstract
Abstract Collagen, particularly atelopeptide collagen, exhibits improved handling characteristics when chemically conjugated and/or crosslinked with a synthetic hydrophilic polymer.
Inventors
- 👤 Woonza Rhee
- 👤 Donald G. Wallace
- 👤 Alan S. Michaels
- 👤 Ramon A. Burns, Jr.
- 👤 Louis Fries
- 👤 Frank DeLustro
- 👤 Hanne Bentz
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 19:27
CPC Classifications
A; A61; A61L; A61L24/00; A61L24/04; A61L24/10; A61L24/102; A61L27/00; A61L27/14; A61L27/22; A61L27/24; A61L27/26; A61L27/28; A61L27/34; A61L27/40; A61L27/44; A61L27/50; A61L27/54; A61L31/00; A61L31/04; A61L31/041; A61L31/043; A61L31/044; A61L31/08; A61L31/10; A61L31/12; A61L31/125; C; C08; C08H; C08H1/00; C08H1/06; C08L; C08L89/00; C08L89/04; C08L89/06; C09; C09J; C09J189/00; C09J189/04; C09J189/06; A61F; A61F2/00; A61F2/02; A61F2/04; A61F2/06; A61F2/07; A61F2310/00; A61F2310/00005; A61F2310/00365; A61L2300/00; A61L2300/40; A61L2300/412; A61L2300/414; A61L2300/60; A61L2300/602; A61L2430/00; A61L2430/02; A61L2430/16; C08L2666/00; C08L2666/02
Claims Analysis
Total Claims: 17
Claim 1
Independent Claim
38 words
A pharmaceutically acceptable composition for replacing or augmenting cartilage, which composition comprises: an effective amount of atelopeptide collagen crosslinked with a hydrophilic synthetic polymer, the composition having a density of about 0.5 to about 1.5 g/cm 3 .
Claim 2
Dependent Claim
38 words
A pharmaceutically acceptable composition for replacing or augmenting cartilage, which composition comprises: an effective amount of atelopeptide collagen crosslinked with a hydrophilic synthetic polymer, the composition having a density of about 0.5 to about 1.5 g/cm 3 .
Claim 3
Dependent Claim
16 words
The composition of claim 1 wherein the collagen is fibrillar atelopeptide collagen or nonfibrillar atelopeptide collagen.
Claim 4
Dependent Claim
103 words
The composition of claim 1, which composition is prepared by the process of: providing an aqueous mixture of collagen having a concentration of about 3 to about 100 mg/mL; adding a concentrated solution of synthetic hydrophilic polymer to form a reaction mixture having a polymer concentration of about 5 to about 40%, by weight, the polymer having first and second ends, the first and second ends each having a reactive group capable of forming a covalent bond with a lysine side chain present on said collagen, wherein the addition results in a crosslinked collagen-polymer conjugate; and removing the conjugate from said reaction mixture.
Claim 5
Dependent Claim
21 words
The composition of claim 3 wherein the polymer is polyethylene glycol having a molecular weight of about 400 to about 20,000.
Claim 6
Dependent Claim
19 words
The composition of claim 4 wherein the polyethylene glycol has a molecular weight of about 3,000 to about 10,000.
Claim 7
Dependent Claim
20 words
The composition of claim 3 wherein the collagen is provided at a concentration of about 10 to about 40 mg/mL.
Claim 8
Dependent Claim
22 words
The composition of claim 3 wherein the collagen is nonfibrillar collagen in solution, and said polymer addition is accompanied by rapid mixing.
Claim 9
Dependent Claim
19 words
The composition of claim 3 wherein the collagen is fibrillar atelopeptide collagen, and the polymer addition is performed slowly.
Claim 10
Dependent Claim
26 words
The composition of claim 8 wherein the reaction mixture is agitated during the formation of the crosslinked collagen-polymer conjugate to form a particulate crosslinked collagen-polymer conjugate.
Claim 11
Dependent Claim
71 words
The composition of claim 1 which further comprises a tissue growth-promoting amount of a biologically active factor selected from the group consisting of epidermal growth factor, transforming growth factor-α, transforming growth factor-β, transforming growth factor-β1, transforming growth factor-β2, platelet-derived growth factor-AA, platelet derived growth factor-AB, platelet-derived growth factor-BB, acidic fibroblast growth factor, basic fibroblast growth factor, insulin-like growth factors, interleukins, colony stimulating factors, erythropoietin, nerve growth factor, interferons, and osteogenic factors.
Claim 12
Dependent Claim
18 words
The composition of claim 1 wherein said polymer is monometyl-polyethylene glycol having a molecular weight of about 5,000.
Claim 13
Dependent Claim
22 words
The composition of claim 11 wherein said monomethyl-polyethylene glycol is chemically conjugated to 10-50% of the available lysine residues on said collagen.
Claim 14
Dependent Claim
47 words
The composition of claim 1 further comprising a suitable particulate material selected from the group consisting of fibrillar crosslinked collagen, gelatin beads, polytetrafluoroethylene beads, silicone rubber beads, hydrogel beads, silicon carbide beads, glass beads, hydroxyapatite particles, tricalcium phosphate particles, or mixtures of hydroxyapatite and tricalcium phosphate particles.
Claim 15
Dependent Claim
35 words
The composition of claim 12 wherein the particulate material comprises hydroxyapatite particles, tricalcium phosphate particles, or mixtures of hydroxyapatite and tricalcium phosphate particles having an average diameter of about 1 to 20 microns in diameter.
Claim 16
Dependent Claim
41 words
A pharmaceutically acceptable, non-immunogenic composition, comprising an effective amount of atelopeptide collagen chemically conjugated to a synthetic hydrophilic polymer, the composition having a density of about 0.5 to about 1.5 g/cm 3 and wherein the polymer is difunctional activated polyethylene glycol.
Claim 17
Dependent Claim
41 words
A pharmaceutically acceptable, non-immunogenic composition, comprising an effective amount of atelopeptide collagen chemically conjugated to a synthetic hydrophilic polymer, the composition having a density of about 0.5 to about 1.5 g/cm 3 and wherein the polymer is difunctional activated polyethylene glycol.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1997-04-18 | 1997-10-18 | 1998-04-19 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2001-04-18 | 2001-10-18 | 2002-04-19 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2005-04-18 | 2005-10-18 | 2006-04-19 | $7700.00 | Window Closed / Lapsed |